Validation Data Gallery
Filter:
Tested Applications
| Positive WB detected in | NIH/3T3 cells, MCF-7 cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:1000-1:6000 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Published Applications
| KD/KO | See 1 publications below |
| WB | See 2 publications below |
| IHC | See 3 publications below |
| IF | See 1 publications below |
Product Information
10687-1-AP targets RERG in WB, IF, IHC, ELISA applications and shows reactivity with human, mouse samples.
| Tested Reactivity | human, mouse |
| Cited Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen | RERG fusion protein Ag1041 相同性解析による交差性が予測される生物種 |
| Full Name | RAS-like, estrogen-regulated, growth inhibitor |
| Calculated molecular weight | 23 kDa |
| Observed molecular weight | 23-26 kDa |
| GenBank accession number | BC007997 |
| Gene Symbol | RERG |
| Gene ID (NCBI) | 85004 |
| RRID | AB_2253772 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q96A58 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol , pH 7.3 |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
RERG (Ras-related and estrogen-regulated growth inhibitor), a gene that encodes a small GTP binding and hydrolyzing protein (GTPase) of the Ras superfamily, is a novel gene that was first reported in breast cancer. RERG gene expression is stimulated by the estrogen receptor alpha (ERalpha), and RERG gene expression is absent in ER-negative breast cancer. RERG can bind and hydrolyze GTP as a GTP/GDP molecular switch, and RERG has been shown to possess growth inhibitory activity in breast cancer cells.
Protocols
| Product Specific Protocols | |
|---|---|
| WB protocol for RERG antibody 10687-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
Front Oncol The NFAT3/RERG Complex in Luminal Breast Cancers Is Required to Inhibit Cell Invasion and May Be Correlated With an Absence of Axillary Lymph Nodes Colonization.
| ||
Breast Cancer Res Treat RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype. | ||
Oncol Rep ERK5‑regulated RERG expression promotes cancer progression in prostatic carcinoma. | ||
Oncotarget MicroRNA-382-5p aggravates breast cancer progression by regulating the RERG/Ras/ERK signaling axis. | ||
Front Med (Lausanne) Missing link between tissue specific expressing pattern of ERβ and the clinical manifestations in LGBLEL |